Stocktoria
ALNYLAM PHARMACEUTICALS, INC. ALNY
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2004-05-28
ALNYLAM PHARMACEUTICALS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.7B | $2.2B | $1.8B | $1.0B | $844.3M |
| R&D expense | $1.3B | $1.1B | $1.0B | $883.0M | $792.2M |
| SG&A expense | $1.2B | $975.5M | $795.6M | $770.7M | $620.6M |
| Operating income | $501.6M | -$176.9M | -$282.2M | -$785.1M | -$708.7M |
| Interest expense | — | — | $121.2M | $156.0M | $143.0M |
| Income tax | $9.4M | -$99.2M | $6.7M | $4.2M | $680,000 |
| Net income | $313.7M | -$278.2M | -$440.2M | -$1.1B | -$852.8M |
| EPS (diluted) | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
| Operating cash flow | $524.1M | -$8.3M | $104.2M | -$541.3M | -$641.7M |
| Free cash flow | $465.4M | -$42.6M | $41.9M | -$613.3M | -$718.1M |
| Cash & equivalents | $1.7B | $966.4M | $812.7M | $866.4M | $820.0M |
| Inventory | $82.7M | $78.5M | $89.1M | $129.0M | $86.4M |
| Total assets | $5.0B | $4.2B | $3.8B | $3.5B | $3.6B |
| Total liabilities | $4.2B | $4.2B | $4.1B | $3.7B | $3.1B |
| Shareholders' equity | $789.2M | $67.1M | -$220.6M | -$158.2M | $588.2M |
Source: SEC EDGAR filings · CIK 0001178670 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.